StockData

Pharming vs Xeris Biopharma

PHAR and XERS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How PHAR and XERS compare

Xeris Biopharma grew revenue faster over the last twelve months (36.3% versus 26.6% for Pharming).

Pharming keeps more of each dollar of sales as profit, with a net margin of 0.76% compared with −5.1% at Xeris Biopharma.

Xeris Biopharma scores higher on the StockData Score (10 against 8 for Pharming), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricPHARXERS
Size and price
Market cap–$3.0B
Share price$12.59$16.70
Change, 1 year−28.5%130%
Change, 5 years51.7%670%
Beta (5Y)0.410.28
Employees50K435
StockData Score
Total score810 (better)
Valuation score00
Growth score24 (better)
Performance score13 (better)
Health score5 (better)3
Dividend score00
Valuation
P/S–9.1×
EV/EBITDA–83.7×
Growth
Revenue growth (TTM)26.6%36.3% (better)
Revenue growth, 5Y average12.1%70.2% (better)
EPS growth, 5Y average−40.8%–
Profitability
Gross margin87.9% (better)86.6%
Operating margin6.9%10.9% (better)
Net margin0.76% (better)−5.1%
FCF margin14.3%–
Return on invested capital–22.1%
Financial health
Net debt / EBITDA–3.45
Interest coverage132× (better)1.3×
Current ratio2.59 (better)1.45
Altman Z-score–3.31
Piotroski F-score78 (better)
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions0.32%59.4%
Held by insiders0.00%5.2%
Insider net buying, 12 months–−$5.8M
Short interest, % of float–5.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.